US64125C1099 - Common Stock

We assign a fundamental rating of **8** out of 10 to **NBIX**. **NBIX** was compared to 577 industry peers in the **Biotechnology** industry. **NBIX** has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: **NBIX** is growing strongly while it also seems undervalued. This makes **NBIX** very considerable for value and growth and quality investing!

In the past 5 years **NBIX** has always been profitable.

Looking at the **Return On Invested Capital**, with a value of **13.81%**, **NBIX** belongs to the top of the industry, outperforming **97.04%** of the companies in the same industry.

Measured over the past 3 years, the **Average Return On Invested Capital** for **NBIX** is below the industry average of **13.57%**.

The 3 year average ROIC (**9.89%**) for **NBIX** is below the current ROIC(**13.81%**), indicating increased profibility in the last year.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 10.26% | ||

ROE | 13.52% | ||

ROIC | 13.81% |

ROA(3y)6.18%

ROA(5y)8.97%

ROE(3y)8.92%

ROE(5y)13.75%

ROIC(3y)9.89%

ROIC(5y)11.96%

The **Gross Margin** of **NBIX** (**98.28%**) is better than **97.91%** of its industry peers.

In the last couple of years the **Gross Margin** of **NBIX** has remained more or less at the same level.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 25.7% | ||

PM (TTM) | 16% | ||

GM | 98.28% |

OM growth 3Y-12.58%

OM growth 5Y20.67%

PM growth 3Y-30.22%

PM growth 5Y23.12%

GM growth 3Y-0.38%

GM growth 5Y-0.21%

Compared to 1 year ago, **NBIX** has more shares outstanding

The debt/assets ratio for **NBIX** has been reduced compared to a year ago.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0 | ||

Debt/FCF | 0 | ||

Altman-Z | 12.76 |

ROIC/WACC1.31

WACC10.52%

With a **Current ratio** value of **4.19**, **NBIX** perfoms like the industry average, outperforming **44.25%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 4.19 | ||

Quick Ratio | 4.08 |

The **Earnings Per Share** has grown by an impressive **91.33%** over the past year.

Measured over the past years, **NBIX** shows a very strong growth in **Earnings Per Share**. The EPS has been growing by **70.09%** on average per year.

The **Revenue** has been growing by **33.13%** on average over the past years. This is a very strong growth!

EPS 1Y (TTM)91.33%

EPS 3Y23.01%

EPS 5Y70.09%

EPS Q2Q%-33.68%

Revenue 1Y (TTM)26.69%

Revenue growth 3Y21.74%

Revenue growth 5Y33.13%

Sales Q2Q%30.37%

Based on estimates for the next years, **NBIX** will show a very strong growth in **Earnings Per Share**. The EPS will grow by **44.72%** on average per year.

The **Revenue** is expected to grow by **15.24%** on average over the next years. This is quite good.

EPS Next Y68.04%

EPS Next 2Y63.51%

EPS Next 3Y54.09%

EPS Next 5Y44.72%

Revenue Next Year17.54%

Revenue Next 2Y16.31%

Revenue Next 3Y16.35%

Revenue Next 5Y15.24%

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

The **Price/Earnings** ratio is **44.51**, which means the current valuation is very expensive for **NBIX**.

When comparing the **Price/Forward Earnings** ratio of **NBIX** to the average of the S&P500 Index (**20.38**), we can say **NBIX** is valued inline with the index average.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 44.51 | ||

Fwd PE | 22.77 |

Based on the **Price/Free Cash Flow** ratio, **NBIX** is valued cheaper than 97.39% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 29.98 | ||

EV/EBITDA | 22.53 |

The low **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

The excellent profitability rating of **NBIX** may justify a higher PE ratio.

A more expensive valuation may be justified as **NBIX**'s earnings are expected to grow with **54.09%** in the coming years.

PEG (NY)0.65

PEG (5Y)0.64

EPS Next 2Y63.51%

EPS Next 3Y54.09%

No dividends for **NBIX**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**NEUROCRINE BIOSCIENCES INC**

NASDAQ:NBIX (8/9/2024, 7:03:03 PM)

After market: 147.32 0 (0%)**147.32**

**+0.59 (+0.4%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap14.83B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 44.51 | ||

Fwd PE | 22.77 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)0.65

PEG (5Y)0.64

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 10.26% | ||

ROE | 13.52% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 25.7% | ||

PM (TTM) | 16% | ||

GM | 98.28% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.64

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 4.19 | ||

Quick Ratio | 4.08 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)91.33%

EPS 3Y23.01%

EPS 5Y

EPS Q2Q%

EPS Next Y68.04%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)26.69%

Revenue growth 3Y21.74%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y